Adjuvant Capital

Portfolio Co Investors 2026 for Adjuvant Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Adjuvant Capital accounts for 11 tracked companies with verified cap-table data, 11 of which disclose round sizes totalling $1.2B. The median disclosed raise is $71M, and the largest is Univercells at $300M, ahead of Curevo ($192M) and Minervax ($127M).

The names that recur most often on these co-invested cap tables are Adjuvant Capital (11 companies), Global Health Investment Fund (2 companies), OrbiMed (2 companies), Sanofi Ventures (2 companies), SFPI (1 company), KKR (1 company). By latest disclosed round, the market skews Series B (3), Series A (3), Series C (2), Growth (1).

Best funded Adjuvant Capital companies

  1. Univercells — $300M (latest: Growth)
  2. Curevo — $192M (latest: Series B)
  3. Minervax — $127M
  4. Pulmocide — $122M (latest: Series C)
  5. Themis Bioscience — $95M (latest: Series D)
  6. Excision BioTherapeutics — $71M (latest: Series A)
  7. DEM BioPharma — $70M (latest: Series A)
  8. Memo Therapeutics — $69M (latest: Series C)
  9. Codagenix — $49M (latest: Series B)
  10. 54gene — $45M (latest: Series B)
  11. LimmaTech Biologics — $37M (latest: Series A)

Adjuvant Capital — related firms and companies (54)

Adjuvant Capital profile · All research reports